






I Recovered From Severe Hair Loss: My 8-Month Regrowth Recovery — Full Timeline, Photos & Treatment Data
Disclaimer
The information, experiences, protocols, and results described herein are based solely on personal anecdotal experience, independent research, and self-reported observations. This content is not intended to diagnose, treat, cure, or prevent any medical condition and should not be interpreted as medical advice, professional healthcare guidance, or a recommendation for treatment.
Any medications, peptides, supplements, or therapies referenced may carry significant health risks, side effects, unknown long-term consequences, or potential interactions. Individuals should consult a licensed physician or qualified medical professional before beginning, stopping, or modifying any medical, pharmaceutical, peptide, or supplement regimen.
No guarantees regarding safety, efficacy, or outcomes. Any person choosing to replicate, imitate, or experiment with the information provided does so entirely at their own risk and assume no responsibility or liability for any injury, illness, adverse reaction, complication, damages, or death that may result from the use or misuse of the information
END OF DISCLAIMER
Introduction
I am a 29 years old male who has been dealing with male pattern baldness or alopecia since I was 22 years old. For over 9 years now l have demonstrated a significant progression of androgenic-pattern alopecia with diffuse thinning involving the frontal scalp, mid-scalp, and vertex/crown regions over time. I have done everything under the sun when it comes to hair treatment PRP, micro-needling, herbal oils, but they never worked. But I have finally found what works for me and I will try to do my best to be as detailed as possible with all my information and every step I took to get the results you’ve seen. My hair restoration protocol consisting of standard pharmacologic therapy with oral Minoxidil, Dutasteride, Pyrithione Zinc 1% Shampoo, and also an extensive peptide-based regenerative protocol of GHK-CU, BPC-157 and TB-500.
The baseline reference photograph from November 2018 (Figure 1) shows a full, dense hairline and preserved follicular density without visible scalp exposure, supporting the absence of significant alopecia prior to military service exposure and associated stressors.
By August 8, 2025 (Figure 2a), I have an estimate of ~70% total cosmetic density loss of my hair and photographic findings are consistent with advanced diffuse alopecia characterized by:
• Severe miniaturization of terminal hairs
• Marked reduction in follicular density across the frontal and vertex scalp
• Significant scalp visibility
• Recession and thinning consistent with chronic inflammatory and androgen-mediated hair loss
• Diffuse shedding pattern suggestive of stress-aggravated alopecia superimposed on androgenic alopecia
And after photographic comparison between August 2025 (Figure 2a), February 12, 2026 (Figure 2b), and March 24, 2026 (Figure 2c) demonstrates measurable improvement in overall scalp coverage and follicular recovery and the degree of improvement observed over approximately 7 months is consistent with a positive pharmacologic response and an extensive peptide-based regenerative protocol.
Protocol
I began to subsequently initiated a comprehensive hair restoration protocol consisting of:
1. Minoxidil (Oral) 2.5mg
Initiated with an accelerated loading phase of 5mg for approximately two weeks followed by maintenance dosing of 2.5mg everyday. Minoxidil utilized as a systemic vasodilatory growth stimulant to prolong the anagen phase and improve perifollicular blood flow.
2. Dutasteride (Oral) 0.5mg
Initiated with an accelerated loading phase for approximately two weeks followed by maintenance dosing every three (3) days. Dutasteride functions as a dual Type I and Type II 5-alpha reductase inhibitor, significantly suppressing dihydrotestosterone (DHT), the primary androgen implicated in follicular miniaturization.
3. Pyrithione Zinc 1% Shampoo (Topical)
Used adjunctively every other day to reduce scalp inflammation, seborrheic dermatitis activity, microbial overgrowth, and perifollicular irritation that may contribute to inflammatory shedding.
4. GHK-CU (SubQ)
I administered repeated doses ranging approximately from 3.5mg to 13mg per administration. GHK-CU is a bioactive copper-binding tripeptide associated in medical literature with:
• Upregulation of wound-healing pathways
• Increased vascular endothelial growth factor (VEGF)
• Improved dermal remodeling
• Stimulation of follicular stem cell activity
• Enhanced extracellular matrix repair
• Reduction in perifollicular inflammation
From a trichological standpoint, GHK-Cu likely contributed to:
• Improved scalp microvascular circulation
• Recovery of partially miniaturized follicles
• Increased terminal hair shaft diameter
• Acceleration of anagen-phase cycling
Based on the photographic progression it demonstrated changes consistent with follicular reactivation and improved scalp coverage following GHK-Cu therapy.
5. BPC-157 (SubQ)
I administered repeated doses ranging approximately from 0.5mg to 2mg per administration. BPC-157 is recognized experimentally for:
• Angiogenic activity
• Nitric oxide pathway modulation
• Anti-inflammatory effects
• Enhanced soft tissue healing
• Cellular regenerative signaling
While direct human evidence for alopecia treatment remains limited, the peptide’s regenerative properties may plausibly support:
• Reduction in inflammatory scalp stress
• Improved perifollicular tissue recovery
• Enhanced scalp healing environment
• Supportive recovery in stress-mediated alopecia conditions
6. TB-500 (SubQ)
I administered repeated doses ranging approximately from 0.5mg to 2mg per administration. TB-500 is a synthetic fragment related to Thymosin Beta-4, a peptide associated with:
• Cellular migration and repair signaling
• Anti-inflammatory modulation
• Tissue regeneration
• Cytoskeletal remodeling
• Enhanced wound-healing responses
Within the context of alopecia recovery, TB-500 may have supported:
• Reduction in chronic inflammatory signaling
• Improved scalp tissue recovery
• Enhanced follicular environment stabilization
Although high-quality clinical data for androgenic alopecia remains limited, the regenerative profile of TB-500 may have functioned synergistically alongside minoxidil, dutasteride, and GHK-Cu.
Dosing Log
The dosing logs provided demonstrate consistent administration over several months with therapeutic exposure sufficient to support biologic activity related to tissue repair, angiogenesis, follicular stimulation, and inflammatory modulation.
Refer to charts for reference of dosage and timeline.
Observed Hair Improvements
August 2025 → February 2026 (approximately 6 months):
• Reduction in diffuse shedding pattern
• Early reversal of follicular miniaturization
• Increased terminal hair caliber noted along frontal and mid-scalp regions
• Partial improvement in crown opacity
February 2026 → March 2026:
• Improved uniformity of hair growth
• Reduced scalp visibility under direct lighting
• Enhanced maturation of previously miniaturized follicles
Overall Estimated Recovery
Compared to the August 2025 photograph, the March 2026 photographs demonstrate an estimated:
• Significant stabilization of active hair loss
• Evidence of successful follicular rescue and reactivation
• Conversion of vellus-like hairs into thicker terminal hairs
Despite persistent thinning at the vertex/crown, the documented response is significant and strongly supportive of therapeutic efficacy.
Overall Impression/Interpretation
My overall impression is that my response to this protocol is consistent with diffuse androgenic alopecia, stress-aggravated telogen effluvium, and chronic inflammatory follicular dysfunction. The observed recovery appears temporally associated with sustained oral minoxidil therapy, dutasteride-mediated DHT suppression, anti-inflammatory scalp management, and long-term regenerative peptide administration. The combined therapeutic regimen likely functioned synergistically to stabilize ongoing hair loss, improve scalp vascularity, reverse partial follicular miniaturization, promote terminal hair regrowth, and improve overall cosmetic scalp coverage.
I believe with continued treatment I would be expected to further stabilize my hair loss and potentially improve density over the subsequent 12–18 months, as hair cycling recovery is gradual and dependent on sustained anagen-phase support.
If you have any questions I will do my best to answer them.